Interestingly, we have found that with the same dose, route, frequency and duration of administration, both inhibiting GLS by CB-839 and knocking down GLS1 via adenovirus significantly ameliorated OVX-induced bone loss but deteriorated age-related osteoporosis in mice. Here, GLS is linked to osteoporosis.